View Older Stories View More Recent Stories

Aug 22, 2022 09:00AM AMGEN TO PRESENT NEW DATA AT ESC CONGRESS 2022 HIGHLIGHTING UP TO 8.5 YEARS OF REPATHA® (EVOLOCUMAB) SAFETY AND TOLERABILITY DATA IN HIGH-RISK ASCVD PATIENT POPULATIONS
Aug 8, 2022 02:18PM Amgen (AMGN) Presents New Tarlatamab Clinical Data At WCLC 2022
Aug 8, 2022 02:17PM AMGEN PRESENTS NEW TARLATAMAB CLINICAL DATA AT WCLC 2022
Aug 7, 2022 04:10AM AMGEN DATA AT WCLC 2022 HIGHLIGHTS POTENTIAL TO DELIVER TRANSFORMATIVE MEDICINES FOR HISTORICALLY DIFFICULT-TO-TREAT LUNG CANCERS
Aug 4, 2022 04:01PM AMGEN REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS
Aug 4, 2022 08:01AM Amgen (AMGN) To Acquire Chemocentryx (CCXI) For $4 Billion In Cash, $52 Per Share
Aug 4, 2022 08:00AM AMGEN TO ACQUIRE CHEMOCENTRYX FOR $4 BILLION IN CASH
Aug 3, 2022 04:06PM Amgen (AMGN) Appoints Michael V. Drake to its Board
Aug 3, 2022 04:05PM AMGEN APPOINTS MICHAEL V. DRAKE TO BOARD OF DIRECTORS
Aug 3, 2022 04:00PM AMGEN ANNOUNCES 2022 THIRD QUARTER DIVIDEND
Aug 2, 2022 04:00PM AMGEN TO WEBCAST INVESTOR MEETING AT WCLC 2022
Aug 1, 2022 04:00PM AMGEN ANNOUNCES WEBCAST OF 2022 SECOND QUARTER FINANCIAL RESULTS
Jun 20, 2022 09:00AM AMGEN FOUNDATION MORE THAN DOUBLES COMMITMENT TO LABXCHANGE, FREE VIRTUAL SCIENCE EDUCATION PLATFORM
Jun 10, 2022 04:15PM AMGEN ANNOUNCES WEBCAST OF GOLDMAN SACHS 43RD ANNUAL HEALTHCARE CONFERENCE
Jun 6, 2022 09:02AM Amgen (AMGN) Announces FDA Approves Riabni, A Biosimilar To Rituxan, For Adults With Moderate To Severe Rheumatoid Arthritis
Jun 6, 2022 09:00AM FDA APPROVES RIABNI™ (RITUXIMAB-ARRX), A BIOSIMILAR TO RITUXAN® (RITUXIMAB), FOR ADULTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS
Jun 5, 2022 08:00AM NEW HEAD-TO-HEAD DATA SHOW VECTIBIX® (PANITUMUMAB) DEMONSTRATED SUPERIOR OVERALL SURVIVAL COMPARED TO BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN JAPANESE PATIENTS WITH WILD-TYPE RAS COLORECTAL C
Jun 3, 2022 04:00PM AMGEN ANNOUNCES WEBCAST OF 2022 JEFFERIES HEALTHCARE CONFERENCE
May 31, 2022 09:02AM Amgen (AMGN) announces positive topline data from the Phase 2 OCEAN study of olpasiran
May 31, 2022 09:00AM AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 2 DATA FOR INVESTIGATIONAL OLPASIRAN IN ADULTS WITH ELEVATED LIPOPROTEIN(a)
May 26, 2022 05:00PM NEW DATA SHOWCASES HOW AMGEN IS ADVANCING ALL ANGLES OF CANCER CARE THROUGH INNOVATIVE ONCOLOGY PORTFOLIO AND PIPELINE AT ASCO 2022
May 12, 2022 08:00AM AMGEN AND LANCE BASS PARTNER TO ENCOURAGE PEOPLE TO DO A 'DOUBLE TAKE' TO RECOGNIZE THE EARLY SIGNS OF PSORIATIC ARTHRITIS
May 6, 2022 04:00PM AMGEN ANNOUNCES WEBCAST OF 2022 BANK OF AMERICA HEALTHCARE CONFERENCE
May 2, 2022 09:00AM AMGEN RELEASES ANNUAL ENVIRONMENTAL, SOCIAL & GOVERNANCE REPORT
Apr 27, 2022 04:01PM AMGEN REPORTS FIRST QUARTER 2022 FINANCIAL RESULTS
Apr 27, 2022 09:02AM Amgen (AMGN) Announces Results From Two Open Label Extension Studies Of Repatha
Apr 27, 2022 09:00AM AMGEN ANNOUNCES RESULTS FROM TWO OPEN LABEL EXTENSION STUDIES OF REPATHA® (EVOLOCUMAB)
Apr 22, 2022 04:00PM AMGEN ANNOUNCES WEBCAST OF 2022 FIRST QUARTER FINANCIAL RESULTS
Apr 18, 2022 04:00PM Amgen (AMGN) Announces Positive Top-line Results From Phase 3 Study Of Abp 654, Biosimilar Candidate To Stelara
Apr 18, 2022 04:00PM AMGEN ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 3 STUDY OF ABP 654, BIOSIMILAR CANDIDATE TO STELARA® (USTEKINUMAB)
Apr 11, 2022 05:34AM Amgen (AMGN) Reports LUMAKRAS CodebreaK 100 Study Shows Two-Year Overall Survival of 32.5% in KRAS Patients
Apr 10, 2022 12:00PM LUMAKRAS® (SOTORASIB) CODEBREAK 100 STUDY SHOWS TWO-YEAR OVERALL SURVIVAL OF 32.5% IN PATIENTS WITH KRAS G12C-MUTATED ADVANCED NON-SMALL CELL LUNG CANCER
Mar 25, 2022 09:00AM AMGEN ANNOUNCES NEW OTEZLA (APREMILAST) DATA AT AAD CONGRESS 2022
Mar 10, 2022 04:00PM Amgen To Present At The 32nd annual Oppenheimer Healthcare Conference
Mar 8, 2022 04:30PM AMGEN TO PRESENT LONG-TERM OUTCOMES FOR LUMAKRAS® (SOTORASIB) IN KRAS G12C-MUTATED NSCLC AT AACR 2022
Mar 7, 2022 04:00PM GLOBAL BIOTECHNOLOGY LEADER AMGEN BREAKS GROUND ON NEW MANUFACTURING FACILITY IN NORTH CAROLINA
Mar 2, 2022 04:15PM AMGEN TO PRESENT AT THE 42ND ANNUAL COWEN HEALTHCARE CONFERENCE
Mar 2, 2022 04:00PM AMGEN ANNOUNCES 2022 SECOND QUARTER DIVIDEND
Feb 26, 2022 11:45AM NEW DATA FURTHER REINFORCE EFFICACY OF TEZSPIRE™ (TEZEPELUMAB-EKKO) IN A BROAD POPULATION OF SEVERE ASTHMA PATIENTS
Feb 22, 2022 04:00PM AMGEN ISSUES INAUGURAL GREEN BOND TO ADVANCE ESG GOALS
Feb 16, 2022 04:00PM AMGEN RECOGNIZED FOR OUTSTANDING ESG PERFORMANCE
Feb 14, 2022 05:01PM Amgen (AMGN) Reports LUMAKRAS Shows Encouraging and Clinically Meaningful Anticancer Activity
Feb 14, 2022 05:00PM LUMAKRAS® (SOTORASIB) SHOWS ENCOURAGING AND CLINICALLY MEANINGFUL ANTICANCER ACTIVITY IN PATIENTS WITH KRAS G12C-MUTATED ADVANCED PANCREATIC CANCER IN CODEBREAK 100 TRIAL
Feb 8, 2022 10:22AM Amgen (AMGN) Outlines Growth Strategy Through 2030
Feb 8, 2022 10:20AM AMGEN OUTLINES GROWTH STRATEGY THROUGH 2030 AT VIRTUAL BUSINESS REVIEW
Feb 8, 2022 08:38AM Amgen (AMGN) plans between $6 billion and $7 billion in share repurchases in 2022
Feb 8, 2022 08:36AM AMGEN PROVIDES LONG-TERM GUIDANCE THROUGH 2030 DURING BUSINESS REVIEW MEETING
Feb 7, 2022 04:01PM AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS
Feb 3, 2022 04:00PM AMGEN TO HOST VIRTUAL BUSINESS REVIEW MEETING
Feb 3, 2022 09:01AM Amgen (AMGN), Plexium Announce Multi-year, Drug Discovery Collaboration To Identify Novel Targeted Protein Degradation Therapies
View More Recent Stories View Older Stories